Bharat Biotech has successfully registered 23,000 participants, moving towards achieving the target of involving 26,000 participants for the Phase III clinical trial of Covid-19 anti-vaccine covaxin. Bharat Biotech is developing
Bharat Biotech has successfully registered 23,000 participants, moving towards achieving the target of involving 26,000 participants for the Phase III clinical trial of Covid-19 anti-vaccine covaxin. Bharat Biotech is developing